NLS Pharmaceutics AG (NLSP)

NASDAQ: NLSP · IEX Real-Time Price · USD
0.270
-0.031 (-10.37%)
At close: Mar 18, 2024, 4:00 PM
0.272
+0.002 (0.82%)
After-hours: Mar 18, 2024, 7:30 PM EDT

Company Description

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders.

The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD).

Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD.

The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist.

NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

NLS Pharmaceutics AG
NLS Pharmaceutics AG logo
Country Switzerland
Founded 2015
IPO Date Jan 29, 2021
Industry Biotechnology
Sector Healthcare
Employees 6
CEO Alexander Zwyer M.B.A.

Contact Details

Address:
The Circle 6, 8058
Zurich, V8 CH-6370
Switzerland
Phone 41-41-618-80-00
Website nlspharma.com

Stock Details

Ticker Symbol NLSP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $4.15
CIK Code 0001783036
CUSIP Number H57830103
ISIN Number CH0523961370
SIC Code 2834

Key Executives

Name Position
Alexander Zwyer M.B.A. President, Chief Executive Officer and Director
Dr. George Apostol M.D. Chief Medical Officer and Global Head of Research and Development
Dr. Eric Konofal M.D., Ph.D. Co-Founder and Chief Scientific Officer
Elena Thyen-Pighin Chief Financial Officer
Dr. Christian C. Wenger Dr. iur., L.L.M., Ph.D. General Counsel

Latest SEC Filings

Date Type Title
Mar 14, 2024 6-K Report of foreign issuer
Mar 11, 2024 6-K Report of foreign issuer
Feb 23, 2024 6-K Report of foreign issuer
Feb 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 12, 2024 6-K Report of foreign issuer
Dec 29, 2023 6-K Report of foreign issuer
Dec 22, 2023 6-K Report of foreign issuer
Dec 6, 2023 6-K Report of foreign issuer
Dec 4, 2023 6-K Report of foreign issuer
Dec 4, 2023 6-K Report of foreign issuer